Lorigerlimab is under clinical development by MacroGenics and currently in Phase II for Squamous Non-Small Cell Lung Cancer. According to GlobalData, Phase II drugs for Squamous Non-Small Cell Lung Cancer have a 49% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Lorigerlimab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Lorigerlimab (MGD-019) is under development for the treatment of squamous non-small cell lung cancer, cutaneous melanoma, metastatic castration resistant prostate cancer, cervical cancer and non-microsatellite instability-high colorectal cancer. The drug candidate is a bi-specific monoclonal antibody which acts by targeting programmed cell death protein 1 (PD1) and cytotoxic T lymphocyte protein 4 (CTLA4). It is based on the dual-affinity re-targeting (DART) technology. It was also under development for the treatment of hematological malignancies. It is administered through intravenous route.
MacroGenics is a biopharmaceutical company which focuses on the development and delivery of novel antibody-based therapeutics for the treatment of cancer, infectious diseases and autoimmune disorders. Its product pipeline includes candidates for the treatment of solid tumors, breast and gastroesophageal cancers, type 1 diabetes, HIV, DART product candidates for the treatment of acute myeloid leukemia and myelodysplastic syndrome; and b-cell malignancies. The company’s product candidates are based on proprietary technology platforms, namely, Cancer Stem Cell Platform, Dual-Affinity Re-Targeting (or DART) and TRIDENT Platform and FC Optimization Platform. It works in collaboration with various pharmaceutical and biotechnology companies to leverage its technology platforms and protein engineering capabilities for development. MacroGenics is headquartered in Rockville, Maryland, the US.
For a complete picture of Lorigerlimab’s drug-specific PTSR and LoA scores, buy the report here.